Skip to content
Search

Latest Stories

GSK faces strike over 'derisory' pay offer

Hundreds of workers at pharmaceutical giant GlaxoSmithKline are set to strike over a "derisory" pay offer way below the level of British inflation, a union said on Wednesday (April 20).

Unite general secretary Sharon Graham accused GSK of "colossal corporate greed" over an effective pay cut in real terms as Britain experiences its highest inflation in 30 years.


GSK said it was "disappointed that the Unite union has taken the decision to strike", adding that the British group "remains committed to... a solution".

It said in a statement: "We recognize the impact inflation rates are having on people around the country and are strongly committed to supporting the skilled people who work in GSK manufacturing."

About 500 Unite members, or around 13 per cent of GSK's UK manufacturing workforce, voted to strike, the drugs group said. GSK said it had offered a four-percent increase in base salary plus one-off awards.

Unite said the pay offer was for 2.75 per cent.

The official annual inflation rate in Britain stands at seven per cent -- and is seen hitting double figures by the end of 2022 -- already sparking widespread concerns over a cost-of-living crisis as food and energy costs rocket.

GSK's net profit came in at £4.4 billion ($5.7 billion) last year, while revenues topped £34 billion.

"Never before have our members at GSK voted for strike action -- their anger is a clear response to the company's colossal corporate greed," said Graham, adding that GSK "expects its workforce to swallow a pay cut in the midst of a cost-of-living crisis".

It comes as chief executive Emma Walmsley seeks to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less